English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Should we give beta-blockers to all patients after myocardial infarction? Beta-blockers have been clearly shown decrease mortality after myocardial infarction, but this was documented more than a quarter of a century ago, before the current revascularisation era, and has become uncertain at the present. Nowadays, the only ironclad indication for cardioprotection with beta-blockers remains heart failure with reduced ejection fraction, the very indication that half a century ago was the only contraindication for beta-blocker therapy.

The prescription retroscope – tools for advocating critical and individualised therapy